KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLoans and Notes ReceivablesLong-Term Debt IssuancesNon-Current ReceivablesReceivables RefundsShares Repurchased
Ratios

Royalty Pharma (RPRX) Non-Current Receivables (2019 - 2025)

Royalty Pharma (RPRX) has disclosed Non-Current Receivables for 7 consecutive years, with $16.2 billion as the latest value for Q4 2025.

  • Quarterly Non-Current Receivables rose 7.15% to $16.2 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $16.2 billion through Dec 2025, up 7.15% year-over-year, with the annual reading at $16.2 billion for FY2025, 7.15% up from the prior year.
  • Non-Current Receivables hit $16.2 billion in Q4 2025 for Royalty Pharma, up from $15.8 billion in the prior quarter.
  • In the past five years, Non-Current Receivables ranged from a high of $16.2 billion in Q4 2025 to a low of $12.6 billion in Q1 2021.
  • Historically, Non-Current Receivables has averaged $14.1 billion across 5 years, with a median of $13.8 billion in 2021.
  • Biggest five-year swings in Non-Current Receivables: rose 17.49% in 2021 and later dropped 7.4% in 2023.
  • Year by year, Non-Current Receivables stood at $13.7 billion in 2021, then decreased by 1.64% to $13.5 billion in 2022, then increased by 4.41% to $14.1 billion in 2023, then grew by 7.37% to $15.1 billion in 2024, then grew by 7.15% to $16.2 billion in 2025.
  • Business Quant data shows Non-Current Receivables for RPRX at $16.2 billion in Q4 2025, $15.8 billion in Q3 2025, and $15.1 billion in Q2 2025.